Table 2. Prevalence of HPV 16/18 for women in each scenario 10, 20 and 50 years after initiation of vaccination (t = 0).
Prevalence of HPV 16/18 for women | 10 years | 20 years | 50 years |
Without vaccination | 20.2% | 20.2% | 20.2% |
Scenario 1 | 14.4% (−28.7%) | 9.8% (−51.7%) | 2.6% (−87.2%) |
Scenario 2 | 13.7% (−32.2%) | 8.31% (−58.9%) | 0.85% (−95.8%) |
Scenario 3 | 11.0% (−45.5%) | 6.05% (−70.0%) | 0.6% (−97.0%) |
Scenario 4 | 10.1% (−50%) | 4.69% (−76.8%) | 0.09% (−99.6%) |
Scenario 5 | 12.2% (−39.6%) | 6.96% (−65.6%) | 0.9% (−95.6%) |
Vaccine coverage was supposed constant in each scenario. In parentheses, % of reduction in HPV prevalence compared to the case without vaccination.